Interplay Bio

Interplay Bio is a biotechnology company that accelerates the development of targeted protein degrader (TPD) drugs using its proprietary LigandPro platform. The company utilizes a protein-agnostic, unbiased screening approach to identify novel small molecule-target interactions. By mapping polypharmacology across a wide array of proteins, including those previously considered undruggable, the platform detects transient and low-affinity interactions to identify hit compounds. This approach is designed to be more cost-effective and faster than traditional high-throughput screening methods, enabling the discovery of new E3 ligase binders, molecular glues, and therapeutic targets.

The platform is used to support pharmaceutical partnerships for lead optimization and drug discovery in therapeutic areas such as oncology, neurodegenerative diseases, and metabolic disorders. By exploiting existing molecule libraries to uncover new protein-small molecule interactions, the company helps partners develop more effective and safer therapeutic candidates. Interplay Bio provides services for target ligand discovery and the development of proprietary binders and molecular glues, leveraging its pipeline of small molecule-protein interactions to advance innovative treatments into clinical stages.